W Arnott
Overview
Explore the profile of W Arnott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Lacourciere Y, Arnott W
J Hum Hypertens
. 1994 Apr;
8(4):283-8.
PMID: 8021909
The effects of nebivolol, a new beta-blocker with vasodilating properties, and hydrochlorothiazide (HCTZ) as monotherapies and in combination on BP and plasma lipids, lipoproteins and apolipoproteins were compared with placebo...
3.
Lacourciere Y, Lefebvre J, Poirier L, ARCHAMBAULT F, Arnott W
Am J Hypertens
. 1994 Feb;
7(2):137-45.
PMID: 8179848
This placebo-controlled multifactorial design trial assessed the antihypertensive efficacy of nebivolol, a novel cardioselective beta 1-blocker with vasodilating properties, and hydrochlorothiazide monotherapy and in combination. After a 4-week placebo period,...
4.
Chouinard G, Arnott W
Can J Psychiatry
. 1993 Sep;
38 Suppl 3:S89-95.
PMID: 7504574
Phase II clinical trials with risperidone have proven it to have a potent antipsychotic effect, improving both positive and negative symptoms of schizophrenia. It was found to have a low...
5.
Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan G, et al.
J Clin Psychopharmacol
. 1993 Feb;
13(1):25-40.
PMID: 7683702
In a double-blind study, 135 inpatients with a diagnosis of chronic schizophrenia were randomly assigned to 8 weeks of treatment with one of six parallel treatments: risperidone (a new central...
6.
Lacourciere Y, Poirier L, Lefebvre J, Provencher P, Arnott W
J Clin Pharmacol
. 1992 Jul;
32(7):660-6.
PMID: 1353507
This double-blind, parallel-group study compared the effects of nebivolol, a novel cardioselective beta-blocker, with those of nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoprotein levels. After a washout...